CCCC is trading 5.2% down at $4.12 as investors lock in profits following a sharp rally driven by clinical trial results.
- The stock's recent gains were fueled by renewed interest in Phase 1 cemsidomide data for relapsed/refractory multiple myeloma.
- Today's pullback follows a 5.6% rally in the previous session, reflecting cooling enthusiasm and a broadly weaker market backdrop.